Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Karpov

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nature|June 7, 2013
Theoretical physics: Sizing up atomsPaul Indelicato, Alexander Karpov
Polymers|December 17, 2024
A Mixture Fraction Approach to Predict Polymer BurningArtem Shaklein, Alexander Karpov, Stanislav Trubachev, et al.
Polymers|August 26, 2022
The Influence of Flame Retardants on Combustion of Glass Fiber-Reinforced Epoxy ResinOleg Korobeinichev, Artem Shaklein, Stanislav Trubachev, et al.
Polymers|March 10, 2022
Experimental and Numerical Study of Downward Flame Spread over Glass-Fiber-Reinforced Epoxy ResinOleg Korobeinichev, Alexander Karpov, Artem Shaklein, et al.
The Journal of Dermatology|October 31, 2014
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 studyMamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, et al.
Polymers|November 11, 2022
Mechanisms of the Action of Fire-Retardants on Reducing the Flammability of Certain Classes of Polymers and Glass-Reinforced Plastics Based on the Study of Their CombustionOleg Korobeinichev, Andrey Shmakov, Alexander Paletsky, et al.
Transplantation|June 24, 2011
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month studyHallvard Holdaas, Lionel Rostaing, Daniel Serón, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nature|June 7, 2013
Theoretical physics: Sizing up atomsPaul Indelicato, Alexander Karpov
Polymers|December 17, 2024
A Mixture Fraction Approach to Predict Polymer BurningArtem Shaklein, Alexander Karpov, Stanislav Trubachev, et al.
Polymers|August 26, 2022
The Influence of Flame Retardants on Combustion of Glass Fiber-Reinforced Epoxy ResinOleg Korobeinichev, Artem Shaklein, Stanislav Trubachev, et al.
Polymers|March 10, 2022
Experimental and Numerical Study of Downward Flame Spread over Glass-Fiber-Reinforced Epoxy ResinOleg Korobeinichev, Alexander Karpov, Artem Shaklein, et al.
The Journal of Dermatology|October 31, 2014
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 studyMamitaro Ohtsuki, Akimichi Morita, Masatoshi Abe, et al.
Polymers|November 11, 2022
Mechanisms of the Action of Fire-Retardants on Reducing the Flammability of Certain Classes of Polymers and Glass-Reinforced Plastics Based on the Study of Their CombustionOleg Korobeinichev, Andrey Shmakov, Alexander Paletsky, et al.
Transplantation|June 24, 2011
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month studyHallvard Holdaas, Lionel Rostaing, Daniel Serón, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
The New England Journal of Medicine|July 10, 2014
Secukinumab in plaque psoriasis--results of two phase 3 trialsRichard G Langley, Boni E Elewski, Mark Lebwohl, et al.
Pageof 1